A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

Leuk Lymphoma. 2016;57(6):1463-6. doi: 10.3109/10428194.2015.1091927. Epub 2015 Oct 15.

¹ a NCIC Clinical Trials Group, Queen's University , Kingston , ON , Canada .
² b Department of Biology , University of New Brunswick , Saint John , NB , Canada .
³ c Department of Medicine , Dalhousie University , Saint John , NB , Canada .
⁴ d Juravinski Cancer Centre , Hamilton , ON , Canada .
⁵ e Department of Medicine, Division of Hematology , University of Alberta , Edmonton , AB , Canada .
⁶ f Department of Medical Oncology and Hematology , Princess Margaret Cancer Centre , Toronto , ON , Canada .
⁷ g Division of Hematology and Hematologic Malignancies , University of Calgary , Calgary , AB , Canada .
⁸ h Astex Pharmaceuticals, Inc. , Dublin , CA , USA , and.
⁹ i Department of Oncology, Saint John Regional Hospital and Department of Medicine , Dalhousie University , Saint John , NB , Canada.

No abstract available

Publication types

1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea
Benzimidazoles
Protein Kinase Inhibitors
Urea
Aurora Kinases